DIACARTA®

TRANSFORMING CANCER CARE WITH

SPOT ON

PRECISION DIAGNOSTICS

RadTox™ Test

Therapy Monitoring During Clinical Cancer Management

Lack of a Clinical Practical Blood Biomarker for Cancer Care Management

In standard cancer care, cancer staging is determined, and therapy strategy is proposed after a patient is diagnosed. However, the therapy effect is typically monitored by imaging for six weeks to three months. Patients often ask this question: ***Is my treatment effective during this time? Does my cancer go away?***

Although imaging can help answer this question, weeks or months, have passed, and patients are left in anxiety all this time. Would it be better to have a near-real-time simple blood assay that can monitor the whole treatment process without changing the standard care but let physicians know what may be happening to their patients? Such a diagnostic aid could be very valuable to physicians.

RadTox™ is such as test!

The test detects cell death during cancer treatment by measuring the cfDNA released from normal and tumor cells. Unlike tumor-specific tests such as sequencing and MRD (molecular residual disease), the RadTox™ test is clinically practical and tells the possible treatment trend based on hundreds of clinical publications.

Cancer management cfDNA/ctDNA monitoring from early to late stage



About RadTox™ Test

The RadTox™ Test score indicates the amount of an individual's cell-free DNA, whose levels change during cancer treatment. Although each person's baseline (before treatment) differs, the cfDNA changes over time can predict the disease progression, therapy efficacy, and prognosis. Here are some of the trends found from multiple clinical studies of different cancer types:

- Baseline cfDNA predicts the prognosis of the cancer patient
- cfDNA generally shoots up during cancer therapy, such as surgery, radiotherapy, and chemotherapy
- cfDNA returns to baseline 3 to 4 weeks after treatment is completed and continues to stay around baseline (e.g., stable disease, SD), increase (progression of disease, PD), or decrease (partial response)

Monitoring the cfDNA changes without changing the standard care offers more collected data that may tell what is going on for the patients. Although the changes of cfDNA are not as specific as ctDNA (circulating DNA), it provides basic trends for the patient without going through complicated ctDNA characterization. The latter takes weeks and costs much more money and leads to longer waiting times.

Clinical Cases Using RadTox™ Monitoring

Here are two real clinical examples of how physicians may benefit from the RadTox™ test.

Case 1

The rectal cancer patient went through chemotherapy between May and July 2019. RaxTox monitoring started in May.

The RadTox score reached its highest in late July and came down in early August. The RadTox score stayed stable till the last monitoring point in November. The patient remains stable condition.



Case 2

The esophageal cancer patient stabilized after treatment. RadTox score stayed low from February to August 2020. The esophageal cancer patient stabilized after treatment. RadTox score stayed low from February to August 2020. Then the RadTox score started to increase when the cancer recurrence occurred.



Suggested Blood Draw Schedule for Cancer Treatment Management

Although different patients have different schedules of therapy and RadTox™ may be applied at different stages, we suggest a RadTox™ test schedule according to the following standard care procedure or a similar designed procedure by the physician without changing the standard practice.



How to order the RadTox Test?

RadTox™ is a laboratory-developed test. It has not been approved by the FDA. Ordering of RadTox™ test is through physicians only on our clinical website, calling DiaCarta clinical lab, or contacting your local sales representatives. Once an order is received, a blood collection package is shipped to the designated address where the patient's blood draw happens. We highly recommend that the blood be shipped back to DiaCarta clinical lab the same day or the next day after blood draw to secure more accurate testing results.